CA
CRSP icon

Calton & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Calton & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,217
Closed -$221K – 450
2025
Q4 		$221K Buy
+4,217
New +$253K 0.03% 401

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Calton & Associates's CRSP Position: Q1 2026 in Review

Calton & Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 4,217 shares — an estimated $221K sold.

Calton & Associates first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $221K in Q4 2025. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Calton & Associates reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Calton & Associates sold 4,217 CRISPR Therapeutics shares in Q1 2026, an estimated $221K.
  • Calton & Associates first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
  • Calton & Associates's CRISPR Therapeutics position peaked at $221K in Q4 2025.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.